References
- Caraceni A, Bertetto O, Labianca R, et al. Episodic (breakthrough) pain prevalence in a population of cancer pain patients. Comparison of clinical diagnoses with the qudei – Italian questionnaire for intense episodic pain. J Pain Symptom Manag 2012;43:833-41
- Zeppetella G, O'Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manag 2000;20:87-92
- Patt RB, Ellison NM. Breakthrough pain in cancer patients: characteristics, prevalence, and treatment. Oncology (Williston Park) 1998;12:1035-46, discussion 1049-52
- Davies AN, Dickman A, Reid C, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 2009;13:331-8
- Portenoy RK, Bruns D, Shoemaker B, Shoemaker SA. Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 2: impact on function, mood, and quality of life. J Opioid Manag 2010;6:109-16
- Yamaguchi T, Shima Y, Morita T, et al. Clinical guideline for pharmacological management of cancer pain: the Japanese Society of Palliative Medicine recommendations. Jpn J Clin Oncol 2013;43:896-909
- Gordon DB, Dahl JL, Miaskowski C, et al. American Pain Society recommendations for improving the quality of acute and cancer pain management: American Pain Society quality of care task force. Arch Intern Med 2005;165:1574-80
- Simpson KH. Opioids for persistent non-cancer pain: recommendations for clinical practice. Br J Anaesthesia 2004;92:326-8
- Zeppetella G. Evidence-based treatment of cancer-related breakthrough pain with opioids. J Natl Compr Canc Netw 2013;11(Suppl 1):S37-43
- Caraceni A, Davies A, Poulain P, et al. Guidelines for the management of breakthrough pain in patients with cancer. J Natl Compr Canc Netw 2013;11(Suppl 1):S29-36
- Rustoen T, Geerling JI, Pappa T, et al. A European survey of oncology nurse breakthrough cancer pain practices. Eur J Oncol Nurs 2013;17:95-100
- Meriggi F, Zaniboni A. Fentanyl for breakthrough cancer pain: where are we? Rev Recent Clin Trials 2013;8:42-7
- Elsner F, Zeppetella G, Porta-Sales J, Tagarro I. Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients. Clin Drug Investig 2011;31:605-18
- Hagelberg NM, Olkkola KT. Fentanyl for breakthrough cancer pain – what's new? Pain 2010;151:565-6.
- Beutlhauser T, Oeltjenbruns J, Schafer M. Breakthrough pain and short-acting opioids. Der Anaesthesist 2013;62:431-9
- Mercadante S, Prestia G, Casuccio A. The use of sublingual fentanyl for breakthrough pain by using doses proportional to opioid basal regimen. Curr Med Res Opin. 2013;29:1527-32
- Mercadante S, Porzio G, Aielli F, et al. The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting. Support Care Canc 2013;21:2335-9